Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries

Soerjomataram, Isabelle; Cabasag, Citadel J.; Bardot, Aude; Fidler-Benaoudia, Miranda M; Miranda‐Filho, Adalberto; Ferlay, Jacques; Parkin, Donald Maxwell; Ranganathan, Rama; Piñeros, Marion; Znaor, Ariana; Mery, Les; Joko-Fru, Yvonne Walburga; Dikshit, Rajesh; Sankaranarayanan, Rengaswamy; Swaminathan, Rajaraman; Bray, Freddie

doi:10.1016/s1470-2045(22)00704-5

Cited by 37 publications

(48 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, cancer mortality rates vary slightly less across countries, 3.4‐fold, ranging from 51 100 000 person‐years in Saudi Arabia to 176 100 000 person‐years in Mongolia. These observations are thought to be attributed to higher cancer fatality rates in LMICs due to late‐stage diagnosis and lack of high‐quality treatment 7 . Moreover, fatal cancers such as stomach and liver are disproportionately represented in LMICs 8 .…”

Section: Acs Research: National and Global Cancer Trendsmentioning

confidence: 99%

“…Source: Ferlay et al 6 These observations are thought to be attributed to higher cancer fatality rates in LMICs due to late-stage diagnosis and lack of high-quality treatment. 7 Moreover, fatal cancers such as stomach and liver are disproportionately represented in LMICs. 8 On balance, these findings underscore the significant variability of cancer impact across the global landscape.…”

Section: Acs Global Cancermentioning

confidence: 99%

See 1 more Smart Citation

A tripartite approach toward ending cancer as we know it, for everyone: An American Cancer Society perspective

Dahut,

Kamal,

Lacasse

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

Gaps in the cancer care continuum are vast, both in the United States and globally. The American Cancer Society orchestrates an integrated, tripartite approach toward improving the lives of cancer patients and their families through research, advocacy, and patient support. With a focus on eradicating cancer disparities, the American Cancer Society aims to scale and deploy best practices worldwide through partnerships, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

show abstract

Section: Acs Research: National and Global Cancer Trendsmentioning

confidence: 99%

Section: Acs Global Cancermentioning

confidence: 99%

A tripartite approach toward ending cancer as we know it, for everyone: An American Cancer Society perspective

Dahut,

Kamal,

Lacasse

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The mutations in TP53 and CDKN2A; overexpression of CCND1, CTTN, and FADD; and copy number alterations (CNAs) at 3q and 11q have been found during the progression of OSCC (Ramos-García, González-Moles, Ayén, González-Ruiz, Gil-Montoya, et al 2019; Ramos-García, González-Moles, Ayén, González-Ruiz, Ruiz-Ávila, et al 2019; González-Moles et al 2020; Zhang et al 2020). Although research on OSCC has made progress in recent years, no significant improvement in survival rates has been observed worldwide, which is mainly due to the late diagnosis of advanced OSCC (Soerjomataram et al 2023). In this case, exploring biomarkers for the malignant transformation of OPMD may provide opportunities for primary prevention and early detection of OSCC, thereby helping to reduce the global incidence of oral cancer (Mello et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Copy Number Alterations Predict Development of OSCC from Oral Leukoplakia

Cai,

Zhang,

et al. 2024

J Dent Res

View full text Add to dashboard Cite

Oral leukoplakia (OLK) is a common type of potentially malignant disorder. Early identification of the malignancy potential leads to a better management of OLK and prediction of development of oral squamous cell carcinoma (OSCC). However, there has been no effective biomarker to assess the risk of malignancy in OLK. Genomic copy number alteration (CNA) is a complex chromosomal structural variation in the genome and has been identified as a potential biomarker in multiple cancers. This study aimed to develop a predictive model for the malignant transformation risk of OLK by copy number analysis. A total of 431 OLK samples with long-term follow-up (median follow-up of 67 mo) from multiple academic centers were analyzed for CNAs. CNA events increased with the severity of hyperplasia, mild dysplasia, moderate dysplasia, and severe dysplasia. More CNA events were present in patients with OLK who later developed OSCC than in those with OLK who did not. By multivariate Cox regression analysis, the OLK of the CNA scorehigh group showed an increased risk of malignant transformation than the CNA scorelow group ( P < 0.001). A CNA score model was developed to accurately predict the prognosis (area under the receiver operating characteristic curve [AUC] = 0.879; 95% confidence interval [CI], 0.799–0.959) and was validated using data from 2 external centers (AUC = 0.836, 95% CI, 0.683–0.989; AUC = 0.876, 95% CI, 0.682–1.000), and all of them showed better prediction performances than histopathological grade in assessing the transformation risk of OLK. Furthermore, we performed CNA models among 4 subgroups of OLK with hyperplasia, mild dysplasia, moderate dysplasia, and severe dysplasia and found that CNA score can accurately predict malignant transformation of different subgroups. CNA score may be a useful biomarker to predict malignant transformation of OLK. Subtyping of OLK by the CNA score could contribute to better management of OLK and predicting development of OSCC.

show abstract

“…1 Survival inequalities have been documented for various cancer types across different countries, with developing countries having a low survival rate for major cancer types. 5 Although there has been some progress in improving the survival of cancer patients in low and middle income countries (LMICs), the ratio of deaths to cases remains disproportionally high. 1 In most LMICs, including those of SSA, ovarian cancer is diagnosed at an advanced stage, due to vague presentation symptoms.…”

Section: Introductionmentioning

confidence: 99%

Ovarian cancer survival in sub‐Saharan Africa by human development index and histological subtypes: A population‐based registry study

Gizaw,

Parkin,

Stöter

et al. 2024

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Ovarian cancer (OC) is the fourth most common cancer of women in sub‐Saharan Africa (SSA), although few data have been published on population‐level survival. We estimate ovarian cancer survival in SSA by human development index and histological subtype, using data from seven population‐based cancer registries in six countries: Kenya (Nairobi and Eldoret), Mauritius, Uganda (Kampala), Cote d'Ivoire (Abidjan), Ethiopia (Addis Ababa) and South Africa (Eastern Cape). A total of 644 cases diagnosed during 2008–2014 were included, with 77% being of epithelial subtypes (range 47% [Abidjan]—80% [Mauritius]). The overall observed survival in the study cohort was 73.4% (95% CI: 69.8, 77.0) at 1 year, 54.4% (95% CI: 50.4, 58.7) at 3 years and 45.0% (95% CI: 41.0, 49.4) at 5 years. Relative survival at Year 1 ranged from 44.4% in Kampala to 86.3% in Mauritius, with a mean for the seven series of 67.4%. Relative survival was highest in Mauritius at 72.2% and lowest in Kampala, Uganda at 19.5%, with a mean of 47.8%. There was no difference in survival by age at diagnosis. Patients from high and medium HDI countries had significantly better survival than those from low HDI countries. Women with cancers of epithelial cell origin had much lower survival compared to women with other histological subtypes (p = .02). Adjusted for the young age of the African patients with ovarian cancer (44% aged <50) survival is much lower than in USA or Europe, and underlines the need for improvements in the access to diagnosis and treatment of OC in SSA.

show abstract

Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries

Cited by 37 publications

References 27 publications

A tripartite approach toward ending cancer as we know it, for everyone: An American Cancer Society perspective

A tripartite approach toward ending cancer as we know it, for everyone: An American Cancer Society perspective

Copy Number Alterations Predict Development of OSCC from Oral Leukoplakia

Ovarian cancer survival in sub‐Saharan Africa by human development index and histological subtypes: A population‐based registry study

Contact Info

Product

Resources

About